Promising targets driving cancer progression, drug resistance, and relapse such as androgen receptor variants, loss of PTEN, and ETS gene rearrangement have already been identified and liquid biopsy might provide a feasible non-invasive and low-risk access to optimized treatment20, 21, 22. Here, AR is linked to cancer.